Premium
Serum Selenium Levels in Malignant Lymphoproliferative Diseases
Author(s) -
Calautti Paolo,
Moschini Giuliano,
Stievano Bianca Maria,
Tomio Luigi,
Calzavara Fulvio,
Perona Giuseppe
Publication year - 1980
Publication title -
scandinavian journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0036-553X
DOI - 10.1111/j.1600-0609.1980.tb01319.x
Subject(s) - selenium , medicine , gastroenterology , lymphoma , malignant lymphoma , malignant disease , lymphoproliferative disorders , chemotherapy , significant difference , selenium deficiency , pathology , immunology , chemistry , cancer , oxidative stress , catalase , organic chemistry , glutathione peroxidase
Serum selenium levels were measured in 38 patients with malignant lymphoproliferative diseases (MLD) and in 34 non‐hospitalized healthy individuals. Selenium was determined by proton induced x‐ray emission. In Hodgkin's disease and non‐Hodgkin malignant lymphoma the mean serum levels of selenium were not different from those of the control group. On the contrary lowered mean serum selenium concentrations were observed in the group with chronic lymphocytic leukaemia (5.2 + 0.7 μg/100 ml) as compared to normal individuals (7.9 + 0.3 μg/100 ml). The difference is highly significant (P < 0.005). A second selenium test was made in 11 out of the 38 patients within 8 weeks from the beginning of radiotherapy or chemotherapy; unchanged levels were found.